KTR Meets GSK Officials In London

KTR met with GSK Consumer Health Global R&D head Franck Riot in London to discuss the growth of GlaxoSmithKline in Telangana and its expansion plans. To support its future goals, Frank Riot said the facility will explore opportunities to expand its presence in Hyderabad.

KTR noted that the company had invested over Rs 710 crore in Hyderabad and had created jobs for about 125 people. Since its establishment in 2016, the facility has witnessed investments of around Rs 340 crore in the last 2 years alone. He assured the company of all support from the State.

In addition to pharmaceutical products, vaccines, and consumer healthcare products, GlaxoSmithKline engages in research, development, and manufacturing.

The company ranked 264th in the Fortune Global 500 list for 2021. GSK had 40 new medicines and 17 new vaccines in development by 2020.

Going forward, the facility will continue to grow out of Hyderabad even as they separate from GSK to be an independent organisation known as Haleon. Haleon will be a global leader focused on consumer health.